top of page

Why train at PSI

yellow seminar.png

Legal Psychedelic Practice

The demand for psychedelic psychotherapy and clinicians that can provide this treatment is profound and will continue to grow as more people discover what is possible through it. While there is a push for FDA approval for substances such as MDMA and psilocybin, there are readily available, legal medicines whose psychedelic potential is unlocked if they are paired with an appropriate therapy modality. Cannabis moves from being a calming or uplifting recreational experience to a very useful psychedelic medicine. We have been working with and testing cannabis as a psychedelic in our clinical settings for years. Due to its legal status, non-medical framework, low cost, availability and precise therapeutic response, we refer to it as THE accessible grassroots psychedelic medicine. 

Yellow%20psych%20therapy_edited_edited.p

Mission Driven Community

You are the answer to the vast need for uniquely trained psychedelic practitioners to provide high quality and efficacious somatic psychedelic therapy. PSI is on a mission to train therapists and bring this work to communities world-wide. Through strength in numbers, we can help one another be successful and, more importantly, make a lasting and real difference in the lives of people in need of mental health support. The PSI Psychedelic Therapists Training Program, a highly accessible program for private practitioners with the passion and desire to bring this work to their community, allows therapists to work together, support each other, and experience the deep satisfaction of providing psychedelic therapy to their clients utilizing the PSIP model. Join us for this incredible professional opportunity and personal journey!

Yellow research_edited.png

Cannabis as a Psychedelic

PSI is a mission driven organization that views the responsible, skillful use of psychedelic medicines as the singularly most important development in modern psychological, spiritual and cultural health. Based on our years of clinical and research experience with a variety of substances, our focus is on the advancement of cannabis-assisted and ketamine-assisted psychotherapy. We view this as an equal but preliminary partner to other advanced psychedelics such as psilocybin. Our mission is the grassroots advancement of high quality psychedelic therapy, and the accessibility of these therapies to all who seek them.

bottom of page